Aug 21 |
Regeneron Faces Setback With FDA Rejection Of Blood-Cancer Treatment
|
Aug 20 |
Regeneron Provides Update on Biologics License Application for Linvoseltamab
|
Aug 20 |
If You Invested $1000 In This Stock 20 Years Ago, You Would Have $130 Thousand Today
|
Aug 17 |
Regeneron Pharmaceuticals' (NASDAQ:REGN) five-year earnings growth trails the incredible shareholder returns
|
Aug 15 |
Alvotech’s biosimilar to Regeneron’s Eylea under EU review
|
Aug 13 |
7 Stocks That Usually Benefit From a Recession
|
Aug 13 |
3 Biotech Stocks Poised for a Comeback After Last Week’s Market Meltdown
|
Aug 12 |
FDA approves Sandoz’s Enzeevu as Eylea biosimilar saga continues
|
Aug 10 |
Is There An Opportunity With Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) 47% Undervaluation?
|
Aug 9 |
HRMY vs. REGN: Which Stock Is the Better Value Option?
|